Education
About Us
Working with TipRanks
Follow Us
Ryvu Therapeutics SA (DE:9Y4)
FRANKFURT:9Y4
RESEARCH TOOLSreports
Total Valuation
Ryvu Therapeutics SA has a market cap or net worth of €178.88M. The enterprise value is ―.
Market Cap€178.88M
Enterprise Value―
Share Statistics
Ryvu Therapeutics SA has 23,120,148 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding23,120,148
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
Ryvu Therapeutics SA’s return on equity (ROE) is -0.35 and return on invested capital (ROIC) is -30.22%.
Return on Equity (ROE)-0.35
Return on Assets (ROA)-0.23
Return on Invested Capital (ROIC)-30.22%
Return on Capital Employed (ROCE)-0.30
Revenue Per Employee142.87K
Profits Per Employee-280.83K
Employee Count328
Asset Turnover0.12
Inventory Turnover8.29
Valuation Ratios
The current PE Ratio of Ryvu Therapeutics SA is -14.05. Ryvu Therapeutics SA’s PEG ratio is 0.58.
PE Ratio-14.05
PS Ratio0.00
PB Ratio2.50
Price to Fair Value4.98
Price to FCF-3.40
Price to Operating Cash Flow-3.89
PEG Ratio0.58
Income Statement
In the last 12 months, Ryvu Therapeutics SA had revenue of 46.86M and earned -92.11M in profits. Earnings per share was -4.02.
Revenue46.86M
Gross Profit29.31M
Operating Income-100.95M
Pretax Income-92.11M
Net Income-92.11M
EBITDA-81.04M
Earnings Per Share (EPS)-4.02
Cash Flow
In the last 12 months, operating cash flow was -114.35M and capital expenditures -10.65M, giving a free cash flow of -125.00M billion.
Operating Cash Flow-114.35M
Free Cash Flow-125.00M
Free Cash Flow per Share-5.41
Dividends & Yields
Ryvu Therapeutics SA pays an annual dividend of €4.919, resulting in a dividend yield of ―
Dividend Per Share€4.919
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.09
52-Week Price Change-40.67%
50-Day Moving Average6.06
200-Day Moving Average8.94
Relative Strength Index (RSI)60.54
Average Volume (3m)0.00
Important Dates
Ryvu Therapeutics SA upcoming earnings date is May 14, 2025, TBA Not Confirmed.
Last Earnings DateMar 13, 2025
Next Earnings DateMay 14, 2025
Ex-Dividend DateOct 09, 2019
Financial Position
Ryvu Therapeutics SA as a current ratio of 3.99, with Debt / Equity ratio of 40.70%
Current Ratio3.99
Quick Ratio3.96
Debt to Market Cap<0.01
Net Debt to EBITDA0.70
Interest Coverage Ratio-1.04K
Taxes
In the past 12 months, Ryvu Therapeutics SA has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
Ryvu Therapeutics SA EV to EBITDA ratio is -15.26, with an EV/FCF ratio of -14.04.
EV to Sales26.39
EV to EBITDA-15.26
EV to Free Cash Flow-14.04
EV to Operating Cash Flow-15.55
Balance Sheet
Ryvu Therapeutics SA has €245.02M in cash and marketable securities with zł72.35M in debt, giving a net cash position of -€172.67M billion.
Cash & Marketable Securities€245.02M
Total Debtzł72.35M
Net Cash-€172.67M
Net Cash Per Share-€7.47
Tangible Book Value Per Share€11.06
Margins
Gross margin is -50.83%, with operating margin of -215.42%, and net profit margin of -196.57%.
Gross Margin-50.83%
Operating Margin-215.42%
Pretax Margin-196.57%
Net Profit Margin-196.57%
EBITDA Margin-172.95%
EBIT Margin-196.36%
Analyst Forecast
The average price target for Ryvu Therapeutics SA is ―, which is 11.43% higher than the current price. The consensus rating is ―
Price Target―
Price Target Upside―
Analyst Consensus―
Analyst Count0
Revenue Growth Forecast―
EPS Growth Forecast―